

<u>FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10</u>	
EV 731062667 US Express Mail Label Number	October 21, 2005 Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

KISIELOW ET AL.

INTERNATIONAL APPLICATION NO: PCT/EP03/00611

FILED: 22 JANUARY 2003

U.S. APPLICATION NO: 10/502,235

35 USC §371 DATE: Herewith

FOR: METHODS OF OBTAINING ISOFORM SPECIFIC EXPRESSION IN
MAMMALIAN CELLS

Mail Stop: Amendment

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT

Sir:


In response to the Restriction Requirement of October 5, 2005, Applicants elect the claims of Group 1, claims 1-12 and 14-20, drawn to a method of expressing a desired isoform of a gene in a mammalian cell, comprising the introduction into said cell of at least a partially double stranded (ds) RNA having at least 95% sequence identity to a common sequence shared by two or more isoforms of said gene and also introducing into said cell a vector expressing the said desired isoform of a gene; and a kit comprising reagents that include the said ds RNA and said vector for said method. This election is made without traverse.

This election is timely made. However, if it is deemed that additional fees are required, the Commissioner is authorized to charge Deposit Account No. 19-0134 in the name of Novartis for any fees due.

Applicants reserve the right to prosecute the subject matter of any non-elected claim groups in one or more divisional applications.

An early and favorable action on the merits is respectfully requested.

Respectfully submitted,



John T. Prince
Attorney for Applicants
Reg. No. 43,019

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(617) 871-3346

Date: October 21, 2005